Find out the key features of the breast tumor microenvironment as well as putative predictive biomarkers established in other tumor types. Insights from both fields could guide future studies to enable personalized breast cancer immunotherapy.
Browsing: predictive biomarker
Targeted sequencing focused on cancer-related genes provides comprehensive assessment of tumor mutational burden, with results comparable to whole-exome sequencing.
NGS-guided assessment of interactions between tumors and the immune system leads to new discoveries…
Dr Hafez Halawani talks to Oncology Central regarding the predictive and prognostic potential of tumor location in metastatic colorectal cancer – a debate that was perpetuated with the presentation of the Venook et al study at the 2016 ASCO meeting.
Long noncoding RNAs to predict survival in acute myeloid leukemia: a step toward personalized medicine?
In this review the authors discuss the potential of noncoding RNAs as novel therapeutic targets and biomarkers in acute myeloid leukemia.
Time for paradigm change in management of hepatocellular carcinoma: is a personalized approach on the horizon?
In this article, the authors discuss the urgent need for paradigm change toward predictive, preventive and personalized medicine for treatment of hepatocellular carcinoma.
This review provides insight into the progress made in treating advanced colorectal cancer with immunotherapeutics and the areas that demand further research to make these drugs more effective in this patient population.
In this interview Paolo A Ascierto and Ramon A de Mello discuss the need for effective biomarkers that predict patient response to treatment, and the possibility that further studies may be required to identify alternative biomarkers and to improve understanding of the host immune system and tumor microenvironment.
Could intratumor heterogeneity be used as a biomarker to predict primary tumor responsiveness and improve initial systemic treatment? Read further in this Editorial from Biomarkers in Medicine.
Retrospective analysis finds association between increased expression of metabolism-associated genes and lack of response to nivolumab in PD-L1- positive renal cell carcinoma.